Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.06.8072PMID 16877740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper

• No Evidence of Genotype-Treatment Interactions between Endocrine Therapies and Adverse Drug Effects in Women with Breast Cancer: Findings from the UK Biobank

  2025cites this paper
• Pharmacogenetics of Toxicities Related to Endocrine Treatment in Breast Cancer: A Systematic Review and Meta-analysis

  2024cites this paper
• Pharmacogenetics of Drugs Used in the Treatment of Cancers

  2022cites this paper
• Explore the distribution of (rs35742686, rs3892097 and rs1065852) genetic polymorphisms of cytochrome P4502D6 gene in the Moroccan population

  2022cites this paper
• Prevalence of CYP2D6*4 and its possible relation to therapeutic outcomes of adjuvant tamoxifen therapy in Egyptian premenopausal women with breast cancer.

  2022cites this paper
• CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Drug Response: A Secondary Analyses of the KARISMA Trial.

  2021cites this paper
• Genetic variation and hot flashes: A systematic review.

  2020cites this paper
• Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics

  2020cites this paper
• CYP2D6 gene polymorphisms and breast cancer risk in Moroccan population: A case-control study

  2020cites this paper
• CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

  2018cites this paper
• Tamoxifentherapie-begleitende CYP 2 D 6-Testung : Outline zum aktuellen wissenschaftlichen

  2018cites this paper
• CYP 2 D 6 Testing in Breast Cancer : Ready for Prime Time ?

  2017cites this paper
• Glaucarubulone glucoside from Castela macrophylla suppresses MCF‐7 breast cancer cell growth and attenuates benzo[a]pyrene‐mediated CYP1A gene induction

  2017cites this paper
• Tamoxifentherapie-begleitende CYP2D6-Testung: Outline zum aktuellen wissenschaftlichen Kenntnisstand // Tamoxifen-therapy and CYP2D6-Testing: The State of Knowledge

  2017cites this paper
• The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis

  2017cites this paper
• Does CYP2D6 Genotyping have a Role in Guiding Tamoxifen Therapy

  2017cites this paper
• Significance of CYP2D Polymorphism

  2017cites this paper
• Incidence of inactive allele CYP2D6*4 among Greek women suffering from hormone-sensitive breast cancer.

  2016cites this paper
• Pharmacogenomics of Breast Cancer

  2016cites this paper
• Should CYP2D6 be genotyped when treating with tamoxifen?

  2016cites this paper
• A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen

  2016cites this paper
• The Role of Pharmacogenomics in Individualized Medicine

  2015cites this paper
• Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer.

  2015cites this paper
• Contribution of ABCB 1 and CYP 2 D 6 Genotypes to the Outcome of Tamoxifen Adjuvant Treatment in Premenopausal Women With Breast Cancer

  2015cites this paper
• Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy

  2015cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22

  2014cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• Tamoxifen and Irinotecan Pharmacogenomics

  2014cites this paper
• Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen.

  2014cites this paper
• PharmGKB summary: tamoxifen pathway, pharmacokinetics

  2013cites this paper
• Pharmacogenetics of Tamoxifen: CYP2D6 Testing in Breast Cancer - Ready for Prime Time?

  2013cites this paper
• Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.

  2013influential citation
• Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

  2013cites this paper
• Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan

  2013cites this paper
• Clinical and biomarker predictors of side effects from tamoxifen

  2012cites this paper
• Oral Chemotherapeutic Agents

  2012cites this paper
• Genetic Variants of CYP 2 D 6 Gene and Cancer Risk : A HuGE Systematic Review and Meta-analysis

  2012cites this paper
• Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

  2012cites this paper
• Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM.

  2012cites this paper
• CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

  2012cites this paper
• CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

  2012cites this paper
• Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy

  2012cites this paper
• Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.

  2012cites this paper
• CYP2D6*4 allele and breast cancer risk: Is there any association?

  2012cites this paper
• CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

  2012cites this paper
• Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis.

  2012cites this paper
• Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients.

  2012cites this paper
• CYP 2 D 6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

  2012cites this paper
• Current and Evolving Therapeutic Options in the Treatment of Early Breast Cancer

  2011cites this paper
• CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.

  2011cites this paper
• Pharmacovigilance Working Party (PhVWP)

  2011cites this paper
• Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

  2011cites this paper
• 5 Current insights in the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anti-cancer drugs

  2011cites this paper
• Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics.

  2011cites this paper
• Current and Evolving Therapeutic Options in the Treatment of Early Breast Cancer

  2011cites this paper
• Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy

  2011cites this paper
• Translating pharmacogenetics to primary care

  2011cites this paper
• Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial

  2011cites this paper
• Tamoxifeno y antidepresivos: ¿Antagonistas en la prevención del cáncer de mama?

  2011cites this paper
• [Antagonism of tamoxifen and antidepressants among women with breast cancer].

  2011cites this paper
• Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs

  2011cites this paper
• Nonestrogenic management of hot flashes.

  2011cites this paper
• Pharmacogenomics of Tamoxifen: Ready for Prime Time?

  2010influential citation
• Pharmacogenomics: bridging the gap between science and practice.

  2010cites this paper
• MECHANISMS OF VARIABILITY IN CYP2D6 METABOLISM: THE CONTRIBUTIONS OF POLYMORPHISMS, COPY NUMBER VARIATIONS AND microRNA

  2010influential citation
• The application of genetics and genomics to cancer prevention.

  2010cites this paper
• Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and Validation

  2010cites this paper
• [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].

  2010cites this paper
• Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

  2010cites this paper
• Overcoming endocrine resistance in breast cancer.

  2010cites this paper
• Polymorphismes du CYP2D6 et tamoxifène : perspectives thérapeutiques dans la prise en charge des cancers du sein hormonodépendants

  2010cites this paper
• Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.

  2010cites this paper
• Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives.

  2010cites this paper
• CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance

  2010cites this paper
• Clinical Practice Decisions in Endocrine Therapy

  2010cites this paper
• Pharmacogenomics: a systems approach

  2010cites this paper
• CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

  2010cites this paper
• Breastcancer:beyondthecutting edge

  2009cites this paper
• Breast cancer: beyond the cutting edge

  2009cites this paper
• American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

  2009cites this paper
• Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.

  2009cites this paper
• Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• Pharmacogenomics of tamoxifen therapy.

  2009cites this paper
• Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer

  2009cites this paper
• Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia

  2009cites this paper
• CYP2D6 and tamoxifen: DNA matters in breast cancer

  2009cites this paper
• Genotype-guided tamoxifen therapy: time to pause for reflection?

  2009cites this paper
• Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.

  2009cites this paper
• Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

  2009cites this paper
• Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer

  2009cites this paper
• CYP2D6 testing in breast cancer: ready for prime time?

  2009cites this paper
• Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.

  2009cites this paper
• Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults.

  2009cites this paper
• Dietary changes after breast cancer in women without hot flashes: a simple and inexpensive way to target tumor and host?

  2009cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• CYP2D6 und Tamoxifen: pharmakogenetische Neuentdeckung eines etablierten Medikaments? / CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug?

  2009cites this paper